TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00816933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: appendectomy according to the number of trocar

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: appendectomy
Description: appendectomy according to the number of trocar
Study: NCT01583101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receiving Highlighted Prompts
Description: Prompts received by physicians were highlighted.
Study: NCT00520611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
Study: NCT02749175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cricoid force sensor monitor system
Description: Comprise of a sensor and a monitor system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cricoid force sensor monitor system
Description: Comprise of a sensor and a sham monitor system
Study: NCT04016038

Intervention type: OTHER
Intervention: a psycho-social investigation
Description: The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.

Intervention type: OTHER
Intervention: a psycho-social investigation
Description: The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
Study: NCT01583101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Receiving Non-highlighted Prompts
Description: Prompts received by physicians were not highlighted.
Study: NCT04645784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting Student-Athletes Mental Wellness
Description: The module addresses: 1) managing your own mental wellness; 2) signs and symptoms of mental health problems; 3) role of student-athletes in creating a positive team environment that is supportive of mental health care seeking; 4) the role of a student-athlete in helping teammates; 5) how to identify emergency and non-emergency mental health situations.
Study: NCT02743923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2
Study: NCT04016038

Intervention type: OTHER
Intervention: a psycho-social investigation
Description: The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
Study: NCT04081220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-7289
Description: Single starting dose with individualized dose titrations throughout
Study: NCT03301844

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Blephapad Combo
Description: Blephapad Combo is used to cleanse, soften, sooth and decongest inflamed eyelids and cilia.~The combo also presents an applicator with a heatable tablet that is applied to the eyelid in order to clean and open occluded Meibomian glands, thereby allowing the production of lipids necessary for a healthy tear film. The heatable tablet is to be used prior to cleansing with Blephapad wipes.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Standard treatment, twice daily for one month, consisting in eyelid hygiene using wet, warm gauze.
Study: NCT01107808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and Vit D
Description: ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, Vit D and Calcium
Description: ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
Study: NCT03519243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131
Description: subcutaneously monthly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131
Description: subcutaneously monthly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131
Description: subcutaneously monthly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mircera
Description: subcutaneously monthly
Study: NCT01164462

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test: rapid finger-stick blood specimen test
Study: NCT03808597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital health promotion intervention
Description: Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
Study: NCT02804139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care plus physical therapy
Description: Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care after C-section with no additional physical therapy.
Study: NCT01312168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Description: CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
Study: NCT01164462

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test: rapid finger-stick blood specimen test

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test: conventional test

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test: conventional test

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test: conventional test
Study: NCT04212364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education
Description: In this intervention, people who use opiates will be trained to be peer educators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narcan Nasal Product
Description: All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narcan Nasal Product
Description: All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
Study: NCT03448159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
Study: NCT04555902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postcard
Description: The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Gift
Description: Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Small Gift
Description: Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Frame and Fear Appeals
Description: The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Frame and Fear Appeals
Description: The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.
Study: NCT04148339

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study: NCT02061696

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vascular Access Device
Description: AXERA 2 Access System with Reduced Manual Compression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Manual Compression
Description: Closure procedure by Manual Compression
Study: NCT00981929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50 mg single oral dose
Study: NCT04570241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Malaria toolkit
Description: Knowledge, attitude, and practice on malaria
Study: NCT03301220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC: daratumumab + rHuPH20
Description: Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
Study: NCT04305444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRM-555
Description: Oral once-daily administration
Study: NCT03185559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relievion Device- Treatment Stimulation
Description: 1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Relievion Device- Sham stimulation
Description: 1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
Study: NCT04247802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backwards Walking (BW) programme
Description: A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A 12 week physiotherapy exercise programme EXCLUDING backwards walking
Study: NCT01312168

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Subtherapeutic CPAP
Description: Subtherapeutic CPAP ventilator, pressure \<3 cmH2O, daily use at sleep, six months
Study: NCT04242199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
Study: NCT04601363

Intervention type: DEVICE
Intervention: Patient Specific Rod
Description: Posterior spinal fusion rod
Study: NCT04551807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified natural cycle
Description: This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed cycle
Description: This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
Study: NCT03248310

Intervention type: BEHAVIORAL
Intervention: Quality of Life Assessments
Description: Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.

Intervention type: BEHAVIORAL
Intervention: Quality of Life Assessments
Description: Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
Study: NCT00692939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD34-selected peripheral blood stem cells transplant
Description: high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Transplant conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Transplant conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Transplant conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Transplant conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Transplant conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Mobilization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Mobilization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mobilization
Study: NCT06766773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compound heating strategy
Description: After the surgery begins, a temperature monitoring device (disposable medical temperature sensor provided by the limited company) is inserted into the patient's nasopharynx to record the core temperature, while activating the water blanket and forced air heating system.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: perioperative mandatory warming measures
Description: perioperative mandatory warming measures
Study: NCT06766617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 75 gr Glucose
Description: 75g of anhydrous glucose dissolved in 375 ml of water (Vittel) mixed with 150mg of U-13C\]-glucose (stable isotope from Eurisotope, France). will be orally taken
Study: NCT06766123

Intervention type: PROCEDURE
Intervention: CABG
Description: All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities

Intervention type: PROCEDURE
Intervention: CABG
Description: All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities
Study: NCT03981900

Intervention type: DRUG
Intervention: Tofacitinib
Description: 5 mg BID, oral administrtaion

Intervention type: DRUG
Intervention: Tofacitinib
Description: tablet form 11mg once daily oral
Study: NCT03400150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon
Description: balloon implantation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control - Marking \& IMRT are standard of care for prostate cancer - there is no study-specific intervention
Study: NCT02291848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-specific CTLs
Description: Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-specific CTLs
Description: Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-specific CTLs- fixed dose
Description: Fixed dose of 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion.
Study: NCT04248335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: single-dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: single-dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: single-dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: single-dose administration
Study: NCT04517838

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tumor tissue samples

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tumor tissue samples
Study: NCT03541902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT01287884

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Venous Blood Gas
Description: patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
Study: NCT03592225

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational workshop
Description: the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
Study: NCT03027414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Sham
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Sham
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Sham
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
Study: NCT03857503

Intervention type: DIAGNOSTIC_TEST
Intervention: iFR
Description: Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures.
Study: NCT02166450

Intervention type: DRUG
Intervention: Nystatin
Description: 100 000 IU every 6 h as a suspension